Author

Miles Parkes

VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMES THAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVE COLITIS REFRACTORY TO TREATMENT WITH ADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBD BIORESOURCE OUTCOMES
VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMES THAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVE COLITIS REFRACTORY TO TREATMENT WITH ADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBD BIORESOURCE OUTCOMES

Miles Parkes  et al.

FACTORS ASSOCIATED WITH CHRONIC ABDOMINAL PAIN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PILOT CROSS-SECTIONAL STUDY
FACTORS ASSOCIATED WITH CHRONIC ABDOMINAL PAIN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PILOT CROSS-SECTIONAL STUDY

Miles Parkes  et al.

THE UK INFLAMMATORY BOWEL DISEASE BIORESOURCE: PROGRESSING FROM GENETICS TO FUNCTION AND CLINICAL TRANSLATION IN CROHN'S DISEASE & ULCERATIVE COLITIS IN ADULTS, YOUNG PEOPLE AND CHILDREN
THE UK INFLAMMATORY BOWEL DISEASE BIORESOURCE: PROGRESSING FROM GENETICS TO FUNCTION AND CLINICAL TRANSLATION IN CROHN'S DISEASE & ULCERATIVE COLITIS IN ADULTS, YOUNG PEOPLE AND CHILDREN

Miles Parkes  et al.

THE HEALTH DATA RESEARCH HUB FOR INFLAMMATORY BOWEL DISEASE - GUT REACTION- 3 YEARS ON
THE HEALTH DATA RESEARCH HUB FOR INFLAMMATORY BOWEL DISEASE - GUT REACTION- 3 YEARS ON

Miles Parkes  et al.

FIRST LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 12,747 PATIENTS IN THE UK IBD BIORESOURCE
FIRST LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 12,747 PATIENTS IN THE UK IBD BIORESOURCE

Miles Parkes  et al.

SECOND LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 3,410 PATIENTS IN THE UK IBD BIORESOURCE
SECOND LINE BIOLOGIC THERAPY IN IBD: A PROPENSITY SCORE ANALYSIS OF 3,410 PATIENTS IN THE UK IBD BIORESOURCE

Miles Parkes  et al.

GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION
GAMMA DELTA T CELL SELECTION BY BUTYROPHILIN-LIKE (BTNL) PROTEINS IS A CONSERVED TRAIT LIMITING IBD PROGRESSION

Miles Parkes  et al.

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE
A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

Miles Parkes  et al.

COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE
COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE

Miles Parkes  et al.

GENOME-WIDE ANALYSIS OF 53,400 PEOPLE WITH IRRITABLE BOWEL SYNDROME HIGHLIGHTS SHARED PATHWAYS WITH NEUROAFFECTIVE TRAITS
GENOME-WIDE ANALYSIS OF 53,400 PEOPLE WITH IRRITABLE BOWEL SYNDROME HIGHLIGHTS SHARED PATHWAYS WITH NEUROAFFECTIVE TRAITS

Miles Parkes  et al.

Item 1 - 10 / 10
1